News
Public · Published
Alnylam Pharmaceuticals Price Target Cut to $240.00/Share From $300.00 by Morgan Stanley
Morgan Stanley cut its price target on Alnylam Pharmaceuticals to $240.00 per share from $300.00, while keeping an Equal-Weight rating on the stock.
Published:
Updated:
What happened
Morgan Stanley cut its price target on Alnylam Pharmaceuticals to $240.00 per share from $300.00, while keeping an Equal-Weight rating on the stock.
Confirmed
Global impact / market context
A lower price target means Morgan Stanley expects less upside for the stock than before, which can make some investors trim positions or demand stronger future results. The unchanged Equal-Weight rating suggests the firm is not negative, just less optimistic on value.
Analyst inference
Analyst price targets feed directly into how investors judge whether a stock looks cheap or expensive. A cut at a large bank can push holders to reassess their expected returns, potentially reducing buying interest until new company results confirm the outlook.
Analyst inference
What to watch
- Watch whether other analysts follow Morgan Stanley in lowering their price targets for Alnylam Pharmaceuticals, which would signal a broader shift in expectations rather than one firm's view. Confirmed
- Watch for company updates on drug sales and pipeline progress, because a price target cut without a formal downgrade often invites debate about whether the lower target was too cautious. Proposed
- Watch the share price reaction, since a target cut from $300 to $240 may change investor positioning if holders reduce exposure while the Equal-Weight rating remains in place. Analyst inference
Evidence
- Original source link unavailable